Marcin R. Dzienis, MBBS, on Update on Pembrolizumab, Carboplatin, and Paclitaxel in HNSCC

March 18, 2024 By The ASCO Post Staff

Marcin R. Dzienis, MBBS, of Australia’s Gold Coast University Hospital, discusses the final analysis of KEYNOTE-B10, a phase IV study in which patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) received a first-line combination regimen of pembrolizumab plus carboplatin and paclitaxel. The regimen demonstrated durable antitumor activity, irrespective of patients’ PD-L1 status (Abstract 3).

Related Content